JIngjing Wang

Dr. JIngjing Wang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
XHXueru Hu
Xueru Hu
JWJIngjing Wang
JIngjing Wang
LJLing Jiang
Ling Jiang
XLXueqi Liu
Xueqi Liu
QGQingmiao Ge
Qingmiao Ge
YWYonggui Wu
Yonggui Wu

3 January 2026 in Inflammation
Verified
Journal Article
Open access
PDF file
ZHZiyun Hu
Ziyun Hu
YMYu Ma
Yu Ma
YWYukai Wang
Yukai Wang
JWJIngjing Wang
JIngjing Wang
XLXinran Liu
Xinran Liu
YWYonggui Wu
Yonggui Wu
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease. Given the limited therapeutic options, identifying novel differentially expressed genes and therapeutic targets is crucial for DN. We performed transcriptome sequencing of kidney tissue from DN patients and applied bioinformatics analyses to identify dysregulated pathways and candidate genes. Transcriptomic analysis revealed significant enrichment of the necroptosis pathway in DN kidney tissues, with Z-DNA binding protein 1 (ZBP1) showing the most pronounced differential expression among pathway-associated genes. Clinical and pathological data were collected from DN patients to evaluate the correlation between ZBP1 expression and key indicators of renal function and injury, thereby assessing its association with DN progression. Our results indicate that ZBP1 expression was significantly upregulated in DN kidney tissues compared to normal peritumour tissue, and correlated with renal tubule injury and renal function. Functional studies demonstrated that ZBP1 knockdown attenuated necroptosis, tubular injury, inflammation, and fibrosis in both db/db mice and high glucose/advanced glycation end products (HG/AGEs)-stimulated MTECs (mouse renal tubular epithelial cells). Mechanistically, ZBP1 directly interacts with receptor interacting protein kinase 3 (RIPK3) to promote necroptotic cell death. Furthermore, we identified ETS proto-oncogene 1 (ETS1) as a transcriptional activator of ZBP1 under HG conditions. In summary, this study identifies ZBP1 as a key mediator of tubular injury, inflammation and fibrosis in DN via RIPK3-dependent necroptosis, highlighting its potential as a therapeutic target.